---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-005223"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2026-08-05T11:02:39+00:00"
generated_at: "2026-08-05T11:06:25.937313+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioCryst Q2 revenue $218.3M, GAAP operating profit $98.5M; raises total revenue guidance

## Summary
- ORLADEYO net revenue $158.2M (+1% YoY); oral pellets shipping to pediatric patients began Aug 3.
- GAAP operating profit $98.5M; non-GAAP operating profit $113.2M; cash $354M.
- Raised FY2026 total revenue guidance to $690-715M; ORLADEYO guidance unchanged $625-645M.
- Completed enrollment in navenibart pivotal study (ALPHA-ORBIT); top-line data expected Q3 2027.
- Licensed navenibart European rights to Neopharmed Gentili for $70M upfront plus milestones/royalties.

## SEC filing metadata
- accession: 0001171843-26-005223
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2026-08-05T11:02:39+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184326005223/0001171843-26-005223-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184326005223/f8k_080526.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-005223
- JSON: https://secwatch.observer/filing/0001171843-26-005223.json
- Plain text: https://secwatch.observer/filing/0001171843-26-005223.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.